Existing medication can restore HIV-affected immune cells The medication, anifrolumab, blocks type 1 interferon and is used to treat systemic lupus erythematosus, SLE, an autoimmune disease.

Living with #HIV: The medication #anifrolumab blocks type 1 interferon and is used to treat systemic lupus erythematosus, SLE, an autoimmune disease.
outragemag.com/existing-med...

#HIV overactivates the #immunesystem, causing long-term dysfunction. New research from Linköping University @liu.se shows the #lupus drug #anifrolumab may restore immune cell function, opening the door to immune repair strategies alongside antivirals. #Immunology www.linkedin.com/posts/drmelv...

NEW RESEARCH—Patient profiles and early response in patients with systemic #lupus erythematosus initiating #anifrolumab: interim analysis from the ongoing multicentre observational REVEAL study bit.ly/4aj9YWz

Plus, linked Comment bit.ly/3ZliHT6
#Medsky #Rheumsky #SLE

LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials To investigate the long-term impact of anifrolumab versus placebo on lupus low disease activity state (LLDAS) and definition of remission in systemic …

www.sciencedirect.com/science/arti...

🌷 “LLDAS and DORIS remission, which are associated with favourable outcomes such as ⬇️damage and mortality in patients with SLE, are attainable and sustainable treatment targets with long-term #anifrolumab treatment.”

#lupus #Rheumsky @ericfmorand.bsky.social

Realmy interesting case of Recalcitrant Dermatomyositis Treated With Anifrolumab

#Dermatomyositis #Anifrolumab #IFN #NXP2+

A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus - PubMed This LTE study represents the longest placebo-controlled clinical trial performed in SLE to date. No new safety findings were identified in the LTE study, supporting the favorable benefit-risk profile...

ReadingRheum 🛋️:

Long term #Anifrolumab for #SLE🦋
🌷🌷🌷🌷🌷🌷
🆗👍2 years! 🗓️🗓️

pubmed.ncbi.nlm.nih.gov/36369793/